Why Timelines Break Down at the Handoffs, Not the Bench

Sarah Sink
Feb 5
3 min read

Most drug development timelines do not fall apart because the science fails.

They break down at the handoffs.

The transition from development to manufacturing.The move from tech transfer into GMP execution.The shift from bulk drug product into sterile fill finish.

Each handoff introduces new teams, new assumptions, and new constraints. If those transitions are not managed deliberately, even the most well-intentioned timelines start to slip.

In complex development programs, execution success is less about how fast teams move and more about how well they transition.

Why Timelines Look Good on Paper

Early timelines are often built with optimism and incomplete information.

That is not a criticism. It is reality.

At the proposal stage, not every method is fully qualified. Not every process risk is visible. Not every fill-finish constraint has been identified. Timelines are estimates based on what is known at that moment.

The problem arises when those early timelines are treated as commitments rather than planning tools.

As programs progress, reality shows up. Methods evolve. Processes change. Fill-finish requirements become clearer. Without built-in flexibility, timelines begin to strain.

Where Execution Commonly Slows Down

Most delays do not come from a single event. They accumulate during transitions.

Common friction points include:

Incomplete method readiness during tech transfer
Assumptions about manufacturing fit that do not hold at scale
Late identification of formulation or container requirements
Fill-finish capacity or scheduling constraints
Quality reviews that uncover gaps in documentation or rationale

Each issue on its own may seem manageable. Together, they create compounding delays.

This is why timelines often feel achievable early and unrealistic later.

The Role of Sterile Fill Finish in Timeline Risk

Sterile fill finish frequently becomes the pressure point.

By the time programs reach fill finish, flexibility is limited and expectations are high. Container choices, fill volumes, filtration strategies, and line availability all have real constraints. Changes at this stage are costly and time-consuming.

When fill-finish considerations are not integrated early into planning, timelines absorb the impact later.

Programs that involve fill-finish SMEs early, even during development, identify risks sooner and avoid last-minute adjustments that derail schedules.

Why Handoffs Matter More Than Speed

Fast execution does not come from rushing transitions. It comes from preparing for them.

Strong programs spend time aligning expectations before handoffs occur. They clarify what is ready, what is still evolving, and what risks remain. They ensure that receiving teams are not surprised by what they inherit.

This approach protects timelines because it reduces rework and decision churn.

In development and manufacturing, clean handoffs matter more than aggressive dates.

The Business Development Perspective

For business development professionals, timelines are one of the most sensitive parts of any partnership.

Sponsors want speed. CDMOs want realism. BD sits in the middle.

When BD understands where timelines typically break down, they can help sponsors set expectations that hold up through execution. They can also help internal teams plan capacity and resources more effectively.

This is not about slowing programs down. It is about preventing avoidable delays.

Strong BD professionals know that credibility is built by delivering what was promised, not by promising what cannot be delivered.

What Strong Programs Do Differently

Programs that stay on track tend to share a few behaviors:

They treat timelines as living plans
They involve SMEs before transitions occur
They integrate fill-finish considerations early
They identify risks at handoffs, not after
They communicate openly when assumptions change

These programs move with momentum because they manage reality, not just projections.

Final Thoughts

Timelines rarely fail because teams are not working hard enough. They fail because transitions were underestimated.

In development, manufacturing, and sterile fill finish, success depends on how well teams prepare for what comes next.

If your team is evaluating CDMOs or comparing proposals, it is worth looking beyond the headline timeline and asking how partners manage handoffs, risks, and transitions throughout the program.

My guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost helps biotech teams assess not just speed, but execution readiness across development, manufacturing, and fill finish.

Because in drug development, momentum is built at the handoffs.

For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl on LinkedIn. Whether you need strategic guidance, tailored business development solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.